Tempus AI (NASDAQ:TEM) Upgraded by Rothschild & Co Redburn to Hold Rating

Rothschild & Co Redburn upgraded shares of Tempus AI (NASDAQ:TEM) to a hold rating in a report published on Tuesday,Zacks reports.

Other analysts have also recently issued reports about the company. Guggenheim upped their target price on Tempus AI from $60.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, July 16th. Piper Sandler raised Tempus AI from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $56.00 to $76.00 in a research report on Tuesday, September 1st. Weiss Ratings cut Tempus AI from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 27th. Stifel Nicolaus decreased their price objective on Tempus AI from $60.00 to $50.00 and set a “hold” rating for the company in a report on Monday, August 3rd. Finally, TD Cowen restated a “buy” rating on shares of Tempus AI in a research report on Wednesday, July 15th. Eleven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $68.71.

Tempus AI Price Performance

Shares of TEM opened at $64.29 on Tuesday. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. Tempus AI has a 1-year low of $40.77 and a 1-year high of $104.32. The stock has a market cap of $11.60 billion, a PE ratio of -44.65 and a beta of 3.72. The firm has a fifty day moving average price of $56.03 and a 200 day moving average price of $52.27.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings data on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million for the quarter, compared to analyst estimates of $379.69 million. During the same quarter last year, the company posted ($0.22) earnings per share. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Tempus AI will post -1.38 EPS for the current year.

Insider Buying and Selling at Tempus AI

In related news, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $69.00, for a total transaction of $207,000.00. Following the transaction, the director owned 31,981 shares of the company’s stock, valued at $2,206,689. This trade represents a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Polovin sold 7,927 shares of the business’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $56.00, for a total value of $443,912.00. Following the completion of the transaction, the executive vice president owned 138,140 shares in the company, valued at $7,735,840. This trade represents a 5.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 1,043,988 shares of company stock valued at $56,963,417. Corporate insiders own 24.26% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its holdings in shares of Tempus AI by 6,379.2% in the second quarter. California State Teachers Retirement System now owns 6,977,205 shares of the company’s stock valued at $404,189,000 after purchasing an additional 6,869,519 shares during the period. Voloridge Investment Management LLC lifted its holdings in shares of Tempus AI by 183.0% during the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after purchasing an additional 1,039,176 shares during the period. AQR Capital Management LLC purchased a new position in Tempus AI in the 2nd quarter valued at $54,020,000. Sumitomo Mitsui Trust Group Inc. grew its position in Tempus AI by 23.4% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 4,326,313 shares of the company’s stock valued at $195,636,000 after buying an additional 821,490 shares during the last quarter. Finally, Amova Asset Management Americas Inc. grew its position in Tempus AI by 23.4% in the 1st quarter. Amova Asset Management Americas Inc. now owns 4,326,313 shares of the company’s stock valued at $195,549,000 after buying an additional 821,490 shares during the last quarter. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.